Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Techniques for Evaluation of AR Transcriptional Output and Recruitment to DNA.

Zhang M, Krause WC, Agoulnik IU.

Methods Mol Biol. 2018;1786:219-236. doi: 10.1007/978-1-4939-7845-8_13.

PMID:
29786796
2.

Erratum: Multiferroic coreshell magnetoelectric nanoparticles as NMR sensitive nanoprobes for cancer cell detection.

Nagesetti A, Rodzinski A, Stimphil E, Stewart T, Khanal C, Wang P, Guduru R, Liang P, Agoulnik I, Horstmyer J, Khizroev S.

Sci Rep. 2017 Oct 26;7(1):14137. doi: 10.1038/s41598-017-12311-9.

3.

Human Relaxin Receptor Is Fully Functional in Humanized Mice and Is Activated by Small Molecule Agonist ML290.

Kaftanovskaya EM, Soula M, Myhr C, Ho BA, Moore SN, Yoo C, Cervantes B, How J, Marugan J, Agoulnik IU, Agoulnik AI.

J Endocr Soc. 2017 Jun;1(6):712-725. doi: 10.1210/js.2017-00112. Epub 2017 May 8.

4.

Multiferroic coreshell magnetoelectric nanoparticles as NMR sensitive nanoprobes for cancer cell detection.

Nagesetti A, Rodzinski A, Stimphil E, Stewart T, Khanal C, Wang P, Guduru R, Liang P, Agoulnik I, Horstmyer J, Khizroev S.

Sci Rep. 2017 May 3;7(1):1610. doi: 10.1038/s41598-017-01647-x. Erratum in: Sci Rep. 2017 Oct 26;7(1):14137.

5.

Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1.

Agoulnik AI, Agoulnik IU, Hu X, Marugan J.

Br J Pharmacol. 2017 May;174(10):977-989. doi: 10.1111/bph.13656. Epub 2016 Nov 30. Review.

6.

Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.

Lopez SM, Agoulnik AI, Zhang M, Peterson LE, Suarez E, Gandarillas GA, Frolov A, Li R, Rajapakshe K, Coarfa C, Ittmann MM, Weigel NL, Agoulnik IU.

Clin Cancer Res. 2016 Aug 1;22(15):3937-49. doi: 10.1158/1078-0432.CCR-15-1983. Epub 2016 Mar 11.

7.

Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists.

Hu X, Myhr C, Huang Z, Xiao J, Barnaeva E, Ho BA, Agoulnik IU, Ferrer M, Marugan JJ, Southall N, Agoulnik AI.

Biochemistry. 2016 Mar 29;55(12):1772-83. doi: 10.1021/acs.biochem.5b01195. Epub 2016 Mar 4.

8.

INPP4B is an oncogenic regulator in human colon cancer.

Guo ST, Chi MN, Yang RH, Guo XY, Zan LK, Wang CY, Xi YF, Jin L, Croft A, Tseng HY, Yan XG, Farrelly M, Wang FH, Lai F, Wang JF, Li YP, Ackland S, Scott R, Agoulnik IU, Hondermarck H, Thorne RF, Liu T, Zhang XD, Jiang CC.

Oncogene. 2016 Jun 9;35(23):3049-61. doi: 10.1038/onc.2015.361. Epub 2015 Sep 28.

9.

Long-Lasting Consequences of Testosterone Exposure.

Agoulnik IU, Agoulnik AI.

Endocrinology. 2015 Oct;156(10):3488-9. doi: 10.1210/en.2015-1719. No abstract available.

10.

Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290.

Huang Z, Myhr C, Bathgate RA, Ho BA, Bueno A, Hu X, Xiao J, Southall N, Barnaeva E, Agoulnik IU, Marugan JJ, Ferrer M, Agoulnik AI.

Front Endocrinol (Lausanne). 2015 Aug 17;6:128. doi: 10.3389/fendo.2015.00128. eCollection 2015.

11.

INPP4B suppresses prostate cancer cell invasion.

Hodgson MC, Deryugina EI, Suarez E, Lopez SM, Lin D, Xue H, Gorlov IP, Wang Y, Agoulnik IU.

Cell Commun Signal. 2014 Sep 25;12:61. doi: 10.1186/s12964-014-0061-y.

12.

Base excision repair of chemotherapeutically-induced alkylated DNA damage predominantly causes contractions of expanded GAA repeats associated with Friedreich's ataxia.

Lai Y, Beaver JM, Lorente K, Melo J, Ramjagsingh S, Agoulnik IU, Zhang Z, Liu Y.

PLoS One. 2014 Apr 1;9(4):e93464. doi: 10.1371/journal.pone.0093464. eCollection 2014.

13.

Determinants of the tumor suppressor INPP4B protein and lipid phosphatase activities.

Lopez SM, Hodgson MC, Packianathan C, Bingol-Ozakpinar O, Uras F, Rosen BP, Agoulnik IU.

Biochem Biophys Res Commun. 2013 Oct 18;440(2):277-82. doi: 10.1016/j.bbrc.2013.09.077. Epub 2013 Sep 23.

14.

Discovery, optimization, and biological activity of the first potent and selective small-molecule agonist series of human relaxin receptor 1 (RXFP1).

Xiao J, Chen CZ, Huang Z, Agoulnik IU, Ferrer M, Southall N, Hu X, Zheng W, Agoulnik AI, Marugan JJ.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Mar 10 [updated 2013 May 8].

15.

Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1.

Xiao J, Huang Z, Chen CZ, Agoulnik IU, Southall N, Hu X, Jones RE, Ferrer M, Zheng W, Agoulnik AI, Marugan JJ.

Nat Commun. 2013;4:1953. doi: 10.1038/ncomms2953.

16.

Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.

Hodgson MC, Vanostran G, Alghamdi S, Poppiti RJ, Agoulnik AI, Agoulnik IU.

PLoS One. 2013 Apr 8;8(4):e60455. doi: 10.1371/journal.pone.0060455. Print 2013.

17.
18.

Identification of small-molecule agonists of human relaxin family receptor 1 (RXFP1) by using a homogenous cell-based cAMP assay.

Chen CZ, Southall N, Xiao J, Marugan JJ, Ferrer M, Hu X, Jones RE, Feng S, Agoulnik IU, Zheng W, Agoulnik AI.

J Biomol Screen. 2013 Jul;18(6):670-7. doi: 10.1177/1087057112469406. Epub 2012 Dec 4.

19.

Androgen receptor footprint on the way to prostate cancer progression.

Hodgson MC, Bowden WA, Agoulnik IU.

World J Urol. 2012 Jun;30(3):279-85. doi: 10.1007/s00345-011-0743-7. Epub 2011 Sep 17. Review.

20.

INPP4B: the new kid on the PI3K block.

Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM.

Oncotarget. 2011 Apr;2(4):321-8. Review.

21.

Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.

Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, Ittmann MM, Weigel NL, Agoulnik IU.

Cancer Res. 2011 Jan 15;71(2):572-82. doi: 10.1158/0008-5472.CAN-10-2314. Epub 2011 Jan 11.

22.

Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis.

Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AI.

Endocr Relat Cancer. 2010 Oct 29;17(4):1021-33. doi: 10.1677/ERC-10-0073. Print 2010 Dec.

23.

Coactivator selective regulation of androgen receptor activity.

Agoulnik IU, Weigel NL.

Steroids. 2009 Aug;74(8):669-74. doi: 10.1016/j.steroids.2009.02.007. Epub 2009 Mar 9.

24.

Relaxin/RXFP1 signaling in prostate cancer progression.

Feng S, Agoulnik IU, Li Z, Han HD, Lopez-Berestein G, Sood A, Ittmann MM, Agoulnik AI.

Ann N Y Acad Sci. 2009 Apr;1160:379-80. doi: 10.1111/j.1749-6632.2008.03793.x.

25.

Relaxin signaling in uterine fibroids.

Li Z, Burzawa JK, Troung A, Feng S, Agoulnik IU, Tong X, Anderson ML, Kovanci E, Rajkovic A, Agoulnik AI.

Ann N Y Acad Sci. 2009 Apr;1160:374-8. doi: 10.1111/j.1749-6632.2008.03803.x.

26.

Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase.

Agoulnik IU, Bingman WE 3rd, Nakka M, Li W, Wang Q, Liu XS, Brown M, Weigel NL.

Mol Endocrinol. 2008 Nov;22(11):2420-32. doi: 10.1210/me.2007-0481. Epub 2008 Sep 11.

27.

Androgen receptor coactivators and prostate cancer.

Agoulnik IU, Weigel NL.

Adv Exp Med Biol. 2008;617:245-55. doi: 10.1007/978-0-387-69080-3_23. Review. No abstract available.

PMID:
18497048
28.

Developmental expression and gene regulation of insulin-like 3 receptor RXFP2 in mouse male reproductive organs.

Feng S, Bogatcheva NV, Truong A, Korchin B, Bishop CE, Klonisch T, Agoulnik IU, Agoulnik AI.

Biol Reprod. 2007 Oct;77(4):671-80. Epub 2007 Jul 5.

PMID:
17615407
29.

Relaxin promotes prostate cancer progression.

Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI.

Clin Cancer Res. 2007 Mar 15;13(6):1695-702.

30.

Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.

Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE 3rd, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL.

Cancer Res. 2006 Nov 1;66(21):10594-602.

31.

Androgen receptor action in hormone-dependent and recurrent prostate cancer.

Agoulnik IU, Weigel NL.

J Cell Biochem. 2006 Oct 1;99(2):362-72. Review.

PMID:
16619264
32.

Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility.

Marcelli M, Stenoien DL, Szafran AT, Simeoni S, Agoulnik IU, Weigel NL, Moran T, Mikic I, Price JH, Mancini MA.

J Cell Biochem. 2006 Jul 1;98(4):770-88.

PMID:
16440331
33.

The role of relaxin in endometrial cancer.

Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI.

Cancer Biol Ther. 2006 Jan;5(1):71-7. Epub 2006 Jan 31.

PMID:
16322684
34.

Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression.

Agoulnik IU, Vaid A, Bingman WE 3rd, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL.

Cancer Res. 2005 Sep 1;65(17):7959-67.

35.

Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer.

Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D, Ayala G.

Prostate. 2005 Nov 1;65(3):276-86.

PMID:
16015593
36.

Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.

Murthy S, Agoulnik IU, Weigel NL.

Prostate. 2005 Sep 1;64(4):362-72.

PMID:
15754350
37.

A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk.

Agoulnik IU, Tong XW, Fischer DC, Körner K, Atkinson NE, Edwards DP, Headon DR, Weigel NL, Kieback DG.

J Clin Endocrinol Metab. 2004 Dec;89(12):6340-7.

PMID:
15579801
38.
39.

Repressors of androgen and progesterone receptor action.

Agoulnik IU, Krause WC, Bingman WE 3rd, Rahman HT, Amrikachi M, Ayala GE, Weigel NL.

J Biol Chem. 2003 Aug 15;278(33):31136-48. Epub 2003 May 27.

40.

A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity.

James AJ, Agoulnik IU, Harris JM, Buchanan G, Tilley WD, Marcelli M, Lamb DJ, Weigel NL.

Mol Endocrinol. 2002 Dec;16(12):2692-705.

PMID:
12456791
41.

A transgenic insertion upstream of sox9 is associated with dominant XX sex reversal in the mouse.

Bishop CE, Whitworth DJ, Qin Y, Agoulnik AI, Agoulnik IU, Harrison WR, Behringer RR, Overbeek PA.

Nat Genet. 2000 Dec;26(4):490-4.

PMID:
11101852
42.

Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer.

Tong X, Engehausen DG, Freund CT, Agoulnik I, Oehler MK, Kim TE, Hasenburg A, Guo Z, Contant CF, Woo SL, Kieback DG.

Hybridoma. 1999 Feb;18(1):93-7.

PMID:
10211795
43.

Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents.

Tong X, Shine DH, Agoulnik I, Freund CT, Hasenburg A, Aguilar-Cordova E, Woo SL, Kieback DG.

Anticancer Res. 1998 Sep-Oct;18(5A):3421-6.

PMID:
9858918
44.

Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients.

Levy T, Agoulnik I, Atkinson EN, Tong XW, Gause HM, Hasenburg A, Runnebaum IB, Stickeler E, Möbus VJ, Kaplan AL, Kieback DG.

Anticancer Res. 1998 May-Jun;18(3A):1345-9.

PMID:
9673338
45.

The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter.

Tong X, Engehausen DG, Freund CT, Agoulnik I, Guo Z, Oehler MK, Kim TE, Hasenburg A, Contant CF, Woo SL, Kieback DG.

Anticancer Res. 1998 Mar-Apr;18(2A):719-25.

PMID:
9615711
46.

Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy.

Tong XW, Engehausen DG, Kaufman RH, Agoulnik I, Contant C, Freund CT, Oehler MK, Kim TE, Hasenburg A, Woo SL, Kieback DG.

Anticancer Res. 1998 Mar-Apr;18(2A):713-8.

PMID:
9615710
47.

Cloning, expression analysis and chromosomal localization of the human nuclear receptor gene GCNF.

Agoulnik IY, Cho Y, Niederberger C, Kieback DG, Cooney AJ.

FEBS Lett. 1998 Mar 6;424(1-2):73-8.

48.

Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy.

Tong XW, Agoulnik I, Blankenburg K, Contant CF, Hasenburg A, Runnebaum LB, Stickeler E, Kaplan AL, Woo SL, Kieback DG.

Anticancer Res. 1997 Mar-Apr;17(2A):811-3.

PMID:
9137412
49.

In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration.

Tong XW, Block A, Chen SH, Contant CF, Agoulnik I, Blankenburg K, Kaufman RH, Woo SL, Kieback DG.

Gynecol Oncol. 1996 May;61(2):175-9.

PMID:
8626129

Supplemental Content

Loading ...
Support Center